去年，Anika Therapeutics Inc表現最佳的業務類別OEM Channel的營收達到64.41M美元。United States的營收貢獻最高，去年達到70.06M美元。最近一個季度，截至2026-06-30，Anika Therapeutics Inc表現最佳的業務類別OEM Channel的營收達到18.70M美元。United States的營收貢獻最高，達到19.80M美元。

業務

營業收入

佔比

年報

年報

單季報

OEM Channel

Commercial Channel

Joint Pain Management

Orthopedic Joint Preservation and Restoration

Non-Orthopedic

Orthobiologics

Surgical

Dermal

Licensing, milestone and contract revenue

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

OEM Channel

64.41M(57.09%)

77.77M(64.86%)

--(--)

Commercial Channel

48.41M(42.91%)

42.14M(35.14%)

--(--)

Joint Pain Management

--(--)

101.93M(61.16%)

97.89M(62.65%)

89.50M(60.56%)

83.03M(63.64%)

--(--)

Orthopedic Joint Preservation and Restoration

--(--)

54.88M(32.93%)

50.40M(32.26%)

48.59M(32.88%)

39.37M(30.18%)

--(--)

Non-Orthopedic

--(--)

9.86M(5.91%)

7.95M(5.09%)

9.70M(6.57%)

8.06M(6.18%)

6.08M(5.31%)

6.07M(5.75%)

Orthobiologics

--(--)

101.00M(88.13%)

93.56M(88.65%)

Surgical

--(--)

5.18M(4.52%)

5.51M(5.23%)

Dermal

--(--)

2.24M(1.96%)

396.00K(0.38%)

Licensing, milestone and contract revenue

--(--)

98.00K(0.09%)

--(--)

地區

營業收入

佔比

年報

年報

單季報

United States

Europe

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

70.06M(62.10%)

82.45M(68.76%)

86.91M(71.95%)

119.15M(76.26%)

113.83M(77.02%)

103.18M(79.09%)

90.30M(78.79%)

85.35M(80.86%)

Europe

22.21M(19.69%)

19.40M(16.18%)

17.31M(14.33%)

20.64M(13.21%)

19.58M(13.25%)

14.18M(10.87%)

14.74M(12.86%)

11.73M(11.11%)

Other

20.55M(18.21%)

18.06M(15.06%)

16.57M(13.72%)

16.45M(10.53%)

14.38M(9.73%)

13.10M(10.04%)

9.56M(8.34%)

8.47M(8.03%)